Xeris Biopharma Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| XERS | AMLX | SUPN | 42C.SI | NBIX | 2M7C.F | |
|---|---|---|---|---|---|---|
| Market cap | 1.91B | 3.69B | 1.64B | 515.12M | 16.81B | 2.87B |
| P/E (TTM) | — | — | — | — | 24.6 | 14.8 |
| Forward P/E | 53.2 | -27.0 | 6.3 | 247.4 | 13.9 | — |
| Price/book | -186.8 | 13.7 | -55.5 | 33.6 | 4.3 | 1.2 |
| Dividend yield | — | — | — | — | — | 3.42% |
| 1-year change | +35.67% | +135.96% | −11.32% | +259.26% | +7.27% | −24.84% |
| Today | +1.06% | +0.68% | +0.21% | −3.09% | +0.73% | +2.61% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All XERS news ›Xeris Pharmaceuticals Q3 2026 Earnings Preview
Xeris Pharmaceuticals (XERS) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open. - Xeris Pharmaceuticals (XERS) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market…
Xeris adds longtime biotech exec to its board
Crain's Chicago Business Xeris adds longtime biotech exec to its board Introducing 40 young leaders already putting their imprint on the businesses, institutions and communities shaping our future.
Xeris Biopharma Holdings, Inc. $XERS Stake Raised by Profund Advisors LLC
Posted by Danessa Lincoln on Nov 2nd, 2026 Read Our Latest Stock Report on Xeris Biopharma Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma…
Xeris (NASDAQ: XERS) names ex-Viatris emerging markets president to its board
Posted by Michael Walen on Nov 2nd, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) appointed Menassie M. Taddese, a former Viatris emerging markets president, to its board on Nov. 2. He also joins the Audit Committee. The board grew…
Xeris Biopharma (NASDAQ:XERS) Stock Jumps 6.8% – Here’s What Happened
Posted by Sarita Garza on Oct 19th, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report)’s share price rose 6.8% during mid-day trading on Monday. The company traded as high as $11.05 and last traded at $11.0160.…
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
RECORLEV (levoketoconazole) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of…
Xeris Biopharma Holdings, Inc. Reports Material Event
Healthcare Triangle, Inc. Announces 1-for-20 Reverse Stock Split as Part of Nasdaq Compliance Plan Greenland Energy Company Announces the Resignation of Roderick McIllree From the Board of Directors BlackRock Capital Allocation Term Trust…
Xeris Biopharma Files Patent Infringement Lawsuits In US District Court - SEC Filing
TradingView Xeris Biopharma Files Patent Infringement Lawsuits In US District Court - SEC Filing
News: Xeros Technology in European breakthrough
Xeros Technology in European breakthrough rotherham business news Monday, October 12, 2026 Most popular articles of the last week Most popular of all time
Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)
Posted by Michael Walen on Oct 19th, 2026 Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com6
- chicagobusiness.com1
- defenseworld.net1
- rothbiz.co.uk1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.